Leaflet: information for the user
meloxicam cinfa 15 mg tabletsEFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
meloxicam cinfa contains the active ingredient meloxicam. Meloxicam belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) used to reduce inflammation and pain in joints and muscles.
Meloxicam is indicated for adults and children 16 years of age and older.
Meloxicam is used for:
If you are unsure about any of the above situations, please contact your doctor.
Warnings and precautions
Consult your doctor or pharmacist before starting to take meloxicam cinfa:
If you have ever experienced a fixed drug eruption (flat, oval-shaped patches with redness and swelling of the skin that usually reappear in the same place, blistering, urticaria, and itching) after taking meloxicam or other oxycam derivatives (e.g., piroxicam).
Warnings
Medicines like meloxicam may be associated with a slight increase in the risk of heart attack (“myocardial infarction”) or stroke (“cerebral infarction”). Any risk is greater at high doses and with prolonged treatment. Do not take more than the recommended dose. Do not take meloxicam for longer than prescribed (see section 3 “How to take meloxicam cinfa”).
If you have heart problems, a previous stroke, or if you think you may be at risk of these diseases, you should discuss treatment with your doctor or pharmacist.
For example, if you:
Stop taking meloxicam as soon as you notice bleeding (causing black stools) or ulcers in your digestive system (causing abdominal pain).
Severe skin rashes that can be life-threatening (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been described with the use of meloxicam, initially appearing as red, circular spots with a central blister.
Other additional signs that may appear are mouth sores, throat, nose, genital, and conjunctivitis (swollen, red eyes).
These life-threatening skin rashes, often accompanied by flu-like symptoms, may progress to form widespread blisters or skin peeling.
The highest risk period for developing severe skin reactions is during the first weeks of treatment. If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of meloxicam, do not use meloxicam again at any time.
If you develop a rash or these skin symptoms, stop taking meloxicam, go to a doctor immediately, and inform them that you are taking this medicine.
Meloxicam is not suitable if you need to relieve acute pain immediately.
Meloxicam may mask the symptoms of an infection (e.g., fever). If you think you may have an infection, see a doctor.
Precautions for use
Since treatment will need to be adjusted, it is essential to consult your doctor before taking meloxicam cinfa in the following cases:
Your doctor will need to monitor your progress during treatment.
Other medicines andmeloxicam cinfa
Since meloxicam may affect or be affected by other medicines, inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine.
Specifically, please inform your doctor or pharmacist if you are taking/have taken or have used any of the following medicines:
Pregnancy, breastfeedingand fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
During the first and second trimesters of pregnancy, your doctor will only prescribe this medicine if it is clearly necessary due to the potential risk of abortion or malformation. In this case, the dose should be kept as low as possible and the duration of treatment should be as short as possible.
During the last three months of pregnancy, this medicine is contraindicated: NEVER take this medicine because it may have severe or even fatal consequences for your fetus/child, especially for their heart, lungs, and/or kidneys, even with a single administration.
If you have taken this medicine while pregnant, you should speak to your doctor/midwife immediately so that they can consider adequate monitoring.
Breastfeeding
This medicine is not recommended during breastfeeding.
Fertility
This medicine may make it more difficult for you to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have difficulty becoming pregnant.
Driving and operating machines
This medicine may cause visual disturbances, including blurred vision, dizziness, drowsiness, vertigo, or other central nervous system disturbances. If you notice these effects, do not drive or operate machines.
meloxicam cinfa contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
meloxicam cinfa contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
The recommended dose is:
Acute arthritis::
7.5 mg of meloxicam (half tablet) once a day. This may be increased to 15 mg of meloxicam (one tablet) once a day.
Rheumatoid arthritis:
15 mg of meloxicam (one tablet) once a day. This may be reduced to 7.5 mg of meloxicam (half tablet) once a day.
Ankylosing spondylitis:
15 mg of meloxicam (one tablet) once a day. This may be reduced to 7.5 mg of meloxicam (half tablet) once a day.
Do not exceed the maximum recommended dose of 15 mg per day.
If any of the situations described under the title “Warnings and precautions” affect you, your doctor may limit your dose to 7.5 mg (half tablet) once a day.
Older patients
If you are an older patient, the recommended dose in long-term treatment for rheumatoid arthritis and ankylosing spondylitis is 7.5 mg (half tablet) once a day.
Patients at increased risk of adverse reactions
If you are a patient at increased risk of adverse reactions, your doctor will start treatment at a dose of 7.5 mg (half tablet) per day.
Patients with kidney problems
If you are a patient on dialysis with severe kidney problems, your dose should not exceed 7.5 mg (half tablet) per day. In patients with mild to moderate kidney problems, there is no need to reduce the dose.
Patients with liver problems
In patients with mild to moderate liver problems, there is no need to reduce the dose.
Use in children and adolescents
This medication should not be administered to children and adolescents under 16 years old.
Consult your doctor or pharmacist if you estimate that the action of meloxicam is too strong or weak, or if after several days you do not notice any improvement.
Administration form
Oral route
The tablets should be swallowed with water or another drink during meals.
The tablet can be divided into equal doses.
If you take more meloxicam cinfa than you should
If you have taken too many tablets or suspect an overdose, contact your doctor or go to the nearest hospital immediately.
The symptoms associated with acute overdose of NSAIDs are usually limited to::
These symptoms usually improve when meloxicam is stopped. Gastrointestinal bleeding may occur.
Severe poisoning may cause severe adverse reactions (see section 4):
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take meloxicam cinfa
Do nottake a double dose to compensate for the missed doses. Simply take the next dose at the usual time.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking meloxicam and consult your doctor or the nearest hospital immediately if you notice:
Any allergic reaction (hypersensitivity) that may appear in the form of:
Any gastrointestinal side effect, especially:
Intestinal bleeding (gastrointestinal hemorrhage), ulcer formation or a hole in the digestive system (perforation) can sometimes be severe and potentially fatal, especially in older people.
If you have previously experienced any gastrointestinal symptoms due to long-term use of NSAIDs, seek medical advice immediately, especially if you are an older person. Your doctor may monitor your progress while you are on treatment.
If you experience vision changes, do not drive or use machines.
General side effects of nonsteroidal anti-inflammatory drugs (NSAIDs)
The use of some nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with a slight increase in the risk of arterial occlusion (thrombotic arterial events), such as heart attack (myocardial infarction) or stroke (apoplexy), particularly at high doses and with long-term treatment.
Cases of fluid retention (edema), high blood pressure (hypertension), and heart failure (cardiac failure) have been reported associated with NSAID treatment.
The most common adverse reactions observed affect the gastrointestinal tract (gastrointestinal events):
After administration of NSAIDs, the following adverse reactions have been reported:
Less frequently, gastric inflammation (gastritis) has been observed.
Side effects of meloxicam active substance of this medicine
Very common: may affect more than 1 in 10 patients
Common: may affect up to 1 in 10 patients
Rare: may affect up to 1 in 100 patients
Rare: may affect up to 1 in 1,000 patients
These side effects may increase the risk of infection and cause symptoms such as bruises or nosebleeds.
Very rare: may affect up to 1 in 10,000 patients
Frequency not known: cannot be estimated from available data
Side effects caused by other nonsteroidal anti-inflammatory drugs (NSAIDs), which have not been seen after taking meloxicam
Changes in kidney structure that cause acute kidney failure:
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet.You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
This medication does not require special conditions for conservation.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of meloxicam cinfa
Appearance of the product and contents of the packaging
Yellow-colored, cylindrical, biconvex, scored, and marked with the code “M1” on one side.
Presented in PVC-PVDC/Aluminum blisters. Each package contains 20 or 500 (clinical package) tablets.
Only some package sizes may be commercially marketed.
Holder of the marketing authorization and responsible manufacturer
Cinfa Laboratories, S.A.
Carretera Olaz-Chipi, 10. Areta Industrial Estate
31620 Huarte (Navarra) - Spain
Last review date of this leaflet:June 2023
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/69094/P_69094.html
QR code to:https://cima.aemps.es/cima/dochtml/p/69094/P_69094.html
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.